Pilot Clinical Trial of Indocyanine Green Fluorescence-Augmented Colonoscopy in High Risk Patients
Rahul A. Sheth(Massachusetts General Hospital), Umar Mahmood(Athinoula A. Martinos Center for Biomedical Imaging), Pedram Heidari(Massachusetts General Hospital), Kevin E. Woods(Cancer Treatment Centers of America), Andrew T. Chan(Harvard University), Daniel C. Chung(Massachusetts General Hospital)
Cited by 4
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study
|The Lancet Public Health|2020|2.3k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
|Nature Biotechnology|1999|1.6k